NCT05872256CompletedPhase 4
A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis
A Demonstration of the Hair and Scalp Benefits of 0.045% Tazarotene/0.01% Halobetasol Lotion in Scalp Psoriasis
Source: ClinicalTrials.gov · Last updated 18 Nov 2023
Brief summary (registry, in English)
The objectives of this research are to demonstrate the following:1. To demonstrate improvement in hair growth and hair appearance following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.2. To demonstrate improvement in scalp itch reduction following 12 weeks of once daily treatment with tazarotene/halobetasol lotion in patients with moderate to severe scalp psoriasis.3. To pictorially demonstrate improvement in moderate to severe scalp psoriasis with 12 weeks of once daily treatment with tazarotene/halobetasol lotion.4. To assessment patient perceptions of the value of a lotion in the treatment of moderate to severe scalp psoriasis.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 14 May 2023
- Start date
- 1 Jun 2023
- Primary completion date
- 13 Nov 2023
- Lead sponsor
- Dermatology Consulting Services, PLLC
- Diseases
- Psoriasis
- NCT number
- NCT05872256
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 20
- From 1 Jun 2023 to the primary completion date, 13 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. Subjects with known allergies or sensitivities to ingredients contained in the test products.
- 2\. Subjects with pustular or erythrodermic psoriasis. 3. Subjects who are pregnant or nursing or planning to become pregnant during the course of the study.
- 4\. Subjects who are currently participating in any other clinical study (i.e., dermal patch, use tests, investigational drug or devices, etc.).
- 5\. Subjects viewed by the investigator as not being able to complete the study. 6. Subjects using any type of lotion, medication, or other topical product to the scalp psoriasis within 2 weeks of study entry.
Who the study is looking for
- 1\. Males or non-pregnant females 18+ years of age. 2. Plaque type moderate to severe scalp psoriasis suitable for topical treatment.
- 3\. Subjects must be in general good health as determined from a medical history.
- 4\. Subjects must read and sign the informed consent form after the nature of the study has been fully explained.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dermatology Consulting Services, PLLC Coordinator of this site? Confirm its status | High Point | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.